PTCT — PTC Therapeutics, Inc.

Summary of PTC Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: Total net product and royalty revenue was $263 million, with Sephience contributing $92 million.
• Full Year 2025 Revenue: Total net product and royalty revenue reached $831 million, exceeding guidance of $750 million to $800 million. Sephience generated $111 million since its launch.
• Operating Expenses: Non-GAAP R&D and SG&A expenses for 2025 were $728 million, below the guidance of $730 million to $760 million.
• Cash Position: Ended 2025 with $1.95 billion in cash, bolstered by the $240 million sale of the remaining Evrysdi royalty.

2. Strategic Updates and Business Highlights

• Sephience Launch: The global launch of Sephience for PKU was a significant success, with broad uptake across patient segments. The company expects to have patients on commercial therapy in 20 to 30 countries by the end of 2026.
• R&D Progress: Positive results from the Phase II PIVOT-HD study of votoplam were reported, and several early-stage programs are progressing, including those from the RNA splicing platform.
• Regulatory Approvals: Sephience received approvals in the U.S., EU, Japan, and other countries in 2025. The Japanese launch is anticipated in Q2 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected product revenue of $700 million to $800 million, representing a 19% to 36% growth year-over-year, primarily from Sephience.
• Expense Guidance: Anticipated non-GAAP R&D and SG&A expenses of $680 million to $720 million for 2026.
• Cash Flow Breakeven: The company aims to reach cash flow breakeven in 2026, supported by strong revenue growth and disciplined expense management.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The DMD franchise faces headwinds from increasing generics, which may impact revenue.
• Vatiquinone Development: The FDA has requested an additional study for vatiquinone, which could delay its approval timeline. The company is working on an open-label study to gather more data.
• Pricing Dynamics: The transition to negotiated pricing in Europe post-free pricing period could impact revenue contributions from Sephience.

5. Notable Q&A Insights

• Sephience Sales Dynamics: The majority of revenue in 2026 is expected to come from the U.S., with contributions from international markets anticipated later in the year.
• Patient Engagement: The company is seeing a resurgence of "lost to follow-up" patients engaging with Sephience, driven by social media awareness and positive real-world experiences.
• Reimbursement Landscape: Favorable reimbursement dynamics have emerged, with many payers offering limited or no prior authorization requirements for Sephience.
• Future Pipeline Focus: PTC is prioritizing its innovative R&D programs, including the NLRP3 and NRF2 programs, while remaining open to business development opportunities to accelerate growth.

Overall, PTC Therapeutics demonstrated strong financial performance and strategic progress in 2025, positioning itself for continued growth in 2026, despite facing challenges in certain areas.